Contrast-Induced Nephropathy
No Results
No Results
processing….
Contrast-induced nephropathy (CIN) is defined as the impairment of renal function—measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value—within 48-72 hours after intravenous contrast administration. [1]
For renal insufficiency to be attributable to contrast administration, it should be acute, usually occurring within 2-3 days (although it has been suggested that renal insufficiency developing up to 7 days post–contrast administration be considered CIN); it should also not be attributable to any other identifiable cause of renal failure. A temporal link is thus implied. [2] Following contrast exposure, SCr levels peak between 2 and 5 days and usually return to normal in 14 days. (See Presentation and Workup.)
CIN is one of the leading causes of hospital-acquired acute kidney injury (AKI). It is associated with a significantly higher risk of in-hospital and 1-year mortality, even in patients who do not need dialysis [3] .
There is a complicated relationship between CIN, comorbidity, and mortality. Most patients who develop CIN do not die from renal failure. [4] Death, if it does occur, is more commonly from either a pre-existing nonrenal complication or a procedural complication.
Many physicians who refer patients for contrast procedures and some who perform the procedure themselves are not fully informed about the risk of CIN. A survey found that fewer than half of referring physicians were aware of potential risk factors, including ischemic heart disease and diabetes mellitus. [5] (See DDx.)
A lack of consensus exists regarding the definition and treatment of CIN. Studies differ in regard to the marker used for renal function (SCr versus estimated glomerular filtration rate [eGFR]), the day of initial measurement and remeasurement of the marker, and the percentage increase used to define CIN. This makes it difficult to compare studies, especially in terms of the efficacy of various treatment modalities. [6] (See Treatment and Medication.)
The reported incidence of CIN might be an underestimation. SCr levels normally rise by day 3 after contrast administration. Most patients do not remain hospitalized for long and there is no specific protocol to order outpatient SCr levels 3-5 days after the procedure.
CT scans with contrast are sometimes withheld for fear of CIN. However, a recent study suggests that this risk may be minimal (see Overview/Epidemiology). [7]
The use of SCr as a marker of renal function has its limitations. Indicators such as the eGFR and cystatin C levels have been considered as alternative and reliable reflectors of existing renal function. [8, 9]
Patients with risk factors for CIN should be educated about the necessity of follow-up care with their physicians with a postprocedure SCr estimation, especially if the initial procedure was done on an outpatient basis.
Prevention centers around avoiding volume depletion. This has led to trials and practices using oral hydration, volume expansion with IV fluids and bicarbonate, and both holding and using diuretics. Other prevention strategies include using alternate imaging methods, minimizing amount of contrast, using iso-osmolar nonionic contrast agents, and administration of the antioxidant acetylcysteine. Routinely holding medications such as angiotensin-converting enzyme inhibitors (ACEIs) or diuretics is not recommended. However, one should try to hold any medication that could be nephrotoxic, such as nonsteroidal anti-inflammatory drugs (NSAIDs). Preemptive hemodialysis or hemodiafiltration has not shown to be of any benefit and is not recommended.
Treatment is mainly supportive and aimed at volume and electrolyte balance. Some patients may require renal replacement therapy, but this need is usually transient.
Contrast media (CM) act on distinct anatomic sites within the kidney and exert adverse effects via multiple mechanisms. They cause a direct cytotoxic effect on the renal proximal tubular cells, enhance cellular damage by reactive oxygen species, and increase resistance to renal blood flow. They also exacerbate renal vasoconstriction, particularly in the deeper portions of the outer medulla. This is especially important in patients with chronic kidney disease (CKD), because their preexisting abnormal vascular pathobiology is made worse by the effects of CM. [10, 11]
Renal (particularly medullary) microcirculation depends on a complex interplay of neural, hormonal, paracrine and autocrine influences. Of note are the vasodilator nitric oxide (NO) and the vasoconstrictors vasopressin, adenosine (when it acts via the high- affinity A1 receptors), angiotensin II, and endothelins. Prostaglandins cause a redistribution of blood flow to the juxtamedullary cortex and, therefore, are protective.
NO, in particular, seems to be very important, with antiplatelet, vasodilatory, insulin sensitizing, anti-inflammatory, and antioxidant properties. It has been suggested that plasma levels of asymmetrical dimethylarginine (ADMA), which is an endogenous inhibitor of all NO synthase isoforms, can be used as a marker of CIN, especially in patients with unfavorable outcomes.
CM-mediated vasoconstriction is the result of a direct action of CM on vascular smooth muscle and from metabolites such as adenosine and endothelin. Additionally, the osmotic property of CM, especially in the tubular lumen, decreases water reabsorption, leading to a buildup of interstitial pressure. This, along with the increased salt and water load to the distal tubules, reduces GFR and causes local compression of the vasa recta. All of this contributes to worsening medullary hypoxemia and renal vasoconstriction in patients who are already volume depleted.
Finally, CM also increases resistance to blood flow by increasing blood viscosity and by decreasing red cell deformability. The resulting intravascular sludging generates local ischemia and causes activation of reactive oxygen species that cause tubular damage at a cellular level.
The ability of different classes of CM to cause CIN is influenced by their osmolality, ionicity (the ability of the contrast media to dissociate in water), and molecular structure. Each of these characteristics, in turn, influences their behavior in body fluid and their potential to cause adverse effects. [12] See Table 1, below.
Table 1. Physiochemical Properties of Contrast Media [13] (Open Table in a new window)
Class of Contrast Agent
Type of Contrast Agent
Iodine Dose
(mg/mL)
Iodine/Particle Ratio
Viscosity
(cPs at 37°C)
Osmolality
(mOsm/kg H2 O)
Molecular Weight (Da)
High-osmolar monomers
(ionic)
Diatrizoate (Renografin)
Ioxithalamate (Telebrix)
370
350
1.5
1.5
2.3
2.5
1870
2130
636
643
Low-osmolar dimers
(ionic)
Ioxaglate (Hexabrix)
320
3
7.5
600
1270
Low-osmolar monomers
(nonionic)
Iohexol (Omnipaque)
Iopamidol (Isovue)
Iomeprol (Iomeron)
Ioversol (Optiray)
Iopromide (Ultravist)
Iopentol (Imagopaque)
350
370
400
350
370
350
3
3
3
3
3
3
10.4
9.4
12.6
9
10
12
780
790
620
790
770
810
821
777
778
807
791
835
Iso-osmolar dimers
(nonionic)
Iodixanol (Visipaque)
Iotrolan (Isovist)
320
320
6
6
11.8
8.5
290
290
1550
1620
Agents are classified as high, low, or iso-osmolar depending on their osmolality in relation to blood. Low-osmolarity contrast media (LOCM) is actually a misnomer, since these agents have osmolalities of 600-900 mOsm/kg and so are 2-3 times more hyperosmolar than blood. High-osmolarity contrast media (HOCM) are 5-7 times more hyperosmolar than blood, with osmolalities greater than 1500 mOsm/kg.
Molecular structure of CM refers to the number of benzene rings. Most CM that were developed in the 1990s are dimers with 2 benzene rings. Dimeric CM, while nonionic and with low osmolarity, have high viscosity, which may influence renal tubular blood flow.
The ratio of iodine to dissolved particles describes an important relationship between opacification and osmotoxicity of the contrast agent. The higher ratios are more desirable. High-osmolar agents have a ratio of 1.5, low-osmolar agents have a ratio of 3, and iso-osmolar agents have the highest ratio, 6.
While the safety of LOCM over HOCM in terms of CIN seems intuitive, clinical evidence of it came from a meta-analysis by Barrett and Carlisle that showed the benefit of using LOCM over HOCM, mostly in high-risk patients. [14] The Iohexol Cooperative Study was a large, prospective, randomized, double-blinded, multicenter trial that compared the risk of developing CIN in patients receiving the low-osmolarity agent iohexol versus the high-osmolarity agent diatrizoate. While the HOCM group was 3.3 times more likely to develop CIN compared with the LOCM group, this was seen only in patients with preexisting CKD (baseline SCr of 1.5 mg/dL or higher). In addition to CKD, other independent risk factors were diabetes mellitus, male sex, and higher contrast volume.
Even within the LOCM category, the risk is not the same for all agents. High-risk patients have a higher likelihood of developing CIN if they receive iohexol than if they receive another agent (ie, iopamidol) in the same class.
A comparison of two iso-osmolar LOCM (iohexol and iodixanol) in the Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media (NEPHRIC study), arguably the most definitive study in this category to date, found that the odds of developing CIN in high-risk patients were almost 9 times greater for the study’s iohexol group than for the iodixanol group. The incidence of CIN was 3% in the iodixanol group versus 26% in the iohexol group. [15] However, these results were not duplicated in some subsequent studies.
When iodixanol was used, the Rapid Protocol for the Prevention of Contrast-Induced Renal Dysfunction (RAPPID) trial found a 21% incidence of CIN, [16] and the Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty (CONTRAST) trial found a 33% incidence of CIN. [17] Finally, the Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography (RECOVER) trial compared the iso-osmolar contrast medium iodixanol to the low-osmolarity agent ioxaglate and found a significantly lower incidence of CIN with iodixanol than with ioxaglate (7.9% vs 17%, respectively). [18]
Thus, although the data are by no means uniform, they seem to suggest that the iso-osmolar contrast agent iodixanol may be associated with smaller increases in SCr and lower rates of CIN when compared with other LOCM, especially in patients with CKD and in those with CKD and diabetes mellitus. [19]
Risk factors for CIN can be divided into patient-related, procedure-related, and contrast-related factors (although the risk factors for CIN are still being identified and remain poorly understood).
Patient-related risk factors are as follows:
Procedure-related risk factors are as follows:
Contrast-related risk factors are as follows:
The single most important patient-related risk factor is preexisting CKD, even more so than diabetes mellitus. [20] Patients with CKD in the setting of diabetes mellitus have a 4-fold increase in the risk of CIN compared with patients without diabetes mellitus or preexisting CKD.
CIN is the third leading cause of hospital-acquired AKI. Decreased renal perfusion causing either prenal injury or acute tubular necrosis is the commonest cause [21] .
Despite numerous studies, the actual incidence of contrast induced nephropathy is not clear. The number varies, depending on the following:
In patients without risk factors, the incidence may be as low as 2%. In those with risk factors, such as diabetes, the rate rises to 9%, and to as high as 90% in patients with diabetic nephropathy. Therefore, the number and the type of preexisting risk factors directly influence the incidence of renal insufficiency. Incidence rates are also procedure dependent, with reports in the literature ranging from 1.6-2.3% for diagnostic interventions to 14.5% overall in patients undergoing coronary intervention. [22]
Although the risk for CIN with CT scans has been a long-standing concern, a retrospective study by Hinson et al of 17,934 emergency department visits from 2009 to 2014 found that IV contrast was not associated with an increased frequency of AKI. Whether patients underwent contrast-enhanced, unenhanced, or no CT, there were no significant differences in the incidence of AKI, dialysis, or mortality, regardless of baseline renal function. [7]
The main strengths of this study were the large number of patients and the use of two controls. However, this was a single-center study and it excluded patients with serum creatinine levels >4.0 mg/dL as well as those with renal transplants.
In another study, of 13,126 patients who underwent percutaneous vascular interventions, the incidence of CIN was noted to be 3%. Of the 400 patients who developed CIN, 26 (6.5%) required dialysis. [23]
While African Americans with diabetic nephropathy have a faster acceleration of end-stage renal disease (ESRD), independent of other variables, race has not been found to be a risk factor for CIN.
The incidence of CIN in patients older than 60 years has been variously reported as 8%-16%. It has also been shown that in patients with acute myocardial infarction (MI) who undergo coronary intervention, age of 75 years or older is an independent risk factor for CIN.
CIN is normally a transient process, with renal function reverting to normal within 7-14 days of contrast administration. Less than one-third of patients develop some degree of residual renal impairment.
Dialysis is required in less than 1% of patients, with a slightly higher incidence in patients with underlying renal impairment (3.1%) and in those undergoing primary percutaneous coronary intervention (PCI) for MI (3%). However, in patients with diabetes and severe renal failure, the rate of dialysis can be as high as 12%.
Of the CIN patients who need dialysis, 18% end up requiring it permanently. However, many of these patients have advanced renal insufficiency and concomitant diabetic nephropathy and would have progressed to needing dialysis regardless of the episode of CIN.
A growing body of knowledge indicates that AKI after contrast medium exposure can be a harbinger of CKD or ESRD. In one observational study that included 3986 patients who underwent coronary angiography, 12.1% of patients experienced contrast-induced AKI, and of those, 18.6% suffered persistent renal damage. [24] The population studied appeared representative of the general population undergoing angiography and the rate of AKI was consonant with other studies. The finding that persistent kidney damage can occur after contrast-induced AKI highlights the potential for acceleration of the progression of kidney injury in individuals with preexisting CKD.
Patients who require dialysis have a considerably worse prognosis, with a reported rate of 35.7% inhospital mortality (compared with 7.1% in the nondialysis group) and a 2-year survival rate of only 19%.
CIN by itself may be an independent mortality risk factor. Following invasive cardiology procedures, patients with normal baseline renal function who develop CIN have reduced survival compared with patients with baseline chronic CKD who do not develop CIN.
In one study of the effect of CIN on long-term mortality after percutaneous coronary intervention in patients with or without CKD, CIN was found to be significantly correlated with long-term mortality in the entire cohort (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.62 to 2.29, P< 0.0001) and in patients with CKD (HR 2.62, 95% CI 1.91 to 3.57, P< 0.0001) but not in patients without CKD (HR 1.23, 95% CI 0.47 to 2.62, P = 0.6). The rate of CIN in patients with CKD was 11% and 2% in patients without CKD. [25]
Gadolinium-based CM (used for magnetic resonance imaging [MRI]), when compared with iodine-based CM, have a similar, if not worse, adverse effect profile in patients with moderate CKD and eGFR of less than 30 mL/min. Their use has been implicated in the development of nephrogenic systemic fibrosis, a chronic debilitating condition with no cure.
A review of 3 series and 4 case reports suggested that the risk of renal insufficiency with gadolinium is similar to that of iodinated radiocontrast dye. The reported incidence varies from 4% in stage 3 CKD to 20% in stage 4 CKD, but may even be worse, as suggested by some investigators. In a study of 57 patients, acute renal failure was seen in 28% of patients in the gadolinium group, compared with 6.5% of patients in the iodinated CM group, despite prophylactic saline and N-acetylcysteine (NAC). [26]
The risk factor profile with gadolinium-based CM is similar to that for iodinated CM; the incidence of acute renal failure is higher in patients with any of the following:
CIN is the result of a complex interplay of many of the above risk factors. The presence of 2 or more risk factors is additive, and the likelihood of CIN rises sharply as the number of risk factors increases. Researchers have tried to quantify the contribution of each risk factor to the ultimate outcome of CIN.
Risk stratification scoring systems have been devised to calculate an individual patient’s risk of developing CIN. This has mostly been done in patients undergoing percutaneous coronary intervention (PCI), especially those with preexisting risk factors. Mehran et al developed a scoring system based on points awarded to each of the following multivariate predictors [27] :
Risk categories by total calculated score, CIN rates, and requirements for dialysis were as follows:
Bartholomew et al worked to create another scoring system and took into consideration the following 8 variables [28] :
Lin et al validated a simpler scoring system for predicting the risk of CIN in patients undergoing emergent percutaneous coronary intervention (PCI). [29] The system consists of the following risk factors, each of which is assigned 1 point:
Risk categories by scores and CIN incidence were as follows:
[Guideline] Kellum JA, Lameire, Aspelin P, et al, for the KDIGO Work Group. Kidney Disease: Improving Global Outcomes .KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kindey Int. 2012 Mar. 2(1):1-138. [Full Text].
Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000 Jan. 11(1):177-82. [Medline].
From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc. 2008 Oct. 83(10):1095-100. [Medline].
Gundlach PJ, van Beek-Peeters JA, Ruissen J, Verberk-Jonkers IJ. [Contrast-induced nephropathy and mortality after contrast-based investigation]. Ned Tijdschr Geneeskd. 2015. 159:A8501. [Medline].
Konen E, Konen O, Katz M, Levy Y, Rozenman J, Hertz M. Are referring clinicians aware of patients at risk from intravenous injection of iodinated contrast media?. Clin Radiol. 2002 Feb. 57(2):132-5. [Medline].
Lakhal K, Ehrmann S, Chaari A, et al. Acute Kidney Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and outcome. J Crit Care. 2011 Dec. 26(6):593-9. [Medline].
Hinson JS, Ehmann MR, Fine DM, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med. 2017 May. 69(5):577-586.e4. [Medline].
Droppa M, Desch S, Blase P, et al. Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol. 2011 Nov. 100(11):1037-43. [Medline].
Ren L, Ji J, Fang Y, et al. Assessment of urinary N-acetyl-β-glucosaminidase as an early marker of contrast-induced nephropathy. J Int Med Res. 2011. 39(2):647-53. [Medline].
Lameier NH. Contrast-induced nephropathy–prevention and risk reduction. Nephrol Dial Transplant. 2006 Jun. 21(6):i11-23. [Medline].
[Guideline] Department of Veteran Affairs, Department of Defense. VA/DoD clinical practice guideline for management of chronic kidney disease in primary care. Available at http://www.guideline.gov/content.aspx?id=48951. December 2014; Accessed: December 14, 2015.
Wong GT, Irwin MG. Contrast-induced nephropathy. Br J Anaesth. 2007 Oct. 99(4):474-83. [Medline].
Guastoni C, De Servi S, D’Amico M. The role of dialysis in contrast-induced nephropathy: doubts and certainties. J Cardiovasc Med (Hagerstown). 2007 Aug. 8(8):549-57. [Medline].
Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993 Jul. 188(1):171-8. [Medline].
Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003 Feb 6. 348(6):491-9. [Medline].
Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003 Jun 18. 41(12):2114-8. [Medline].
Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol. 2008 Feb. 21(1):74-85. [Medline].
Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006 Sep 5. 48(5):924-30. [Medline].
Shin DH, Choi DJ, Youn TJ, et al. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography. Am J Cardiol. 2011 Jul 15. 108(2):189-94. [Medline].
Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci. 2007 Oct. 334(4):283-90. [Medline].
Mehta RL, Pascual MT, Soroko S, et al, for the Program to Improve Care in Acute Renal Disease. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004 Oct. 66(4):1613-21. [Medline].
McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997 Nov. 103(5):368-75. [Medline].
Grossman PM, Ali SS, Aronow HD, et al. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Interv Cardiol. 2017 Jun. 30(3):274-80. [Medline].
Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012 Jun 26. 125(25):3099-107. [Medline].
Abe M, Morimoto T, Akao M, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014 Aug 1. 114(3):362-8. [Medline].
Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv. 2006 Feb. 67(2):175-80. [Medline].
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6. 44(7):1393-9. [Medline].
Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004 Jun 15. 93(12):1515-9. [Medline].
Lin KY, Zheng WP, Bei WJ, et al. A novel risk score model for prediction of contrast-induced nephropathy after emergent percutaneous coronary intervention. Int J Cardiol. 2017 Mar 1. 230:402-12. [Medline].
Moreau JF, Noel LH, Droz D. Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called “osmotic nephrosis”. Invest Radiol. 1993 Feb. 28(2):187-90. [Medline].
Xu Y, Zheng X, Liang B, Gao J, Gu Z. Vitamins for prevention of contrast-induced acute kidney injury: a systematic review and trial sequential analysis. Am J Cardiovasc Drugs. 2018 Oct. 18(5):373-86. [Medline].
Liu X, Hang Y, Shen L, et al. Prevention of contrast-induced nephropathy with prostaglandin E1 in patients undergoing percutaneous coronary procedures: A meta-analysis of 24 randomized controlled trials . Clin Nephrol. 2018 Nov. 90(5):313-24. [Medline].
Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016 Mar 15. 164(6):406-16. [Medline].
Solomon R. Radiocontrast-induced nephropathy. Semin Nephrol. 1998 Sep. 18(5):551-7. [Medline].
Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl. 2006 Apr. S16-9. [Medline].
Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006 Jun 21. 295(23):2765-79. [Medline].
Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1. 389(10076):1312-22. [Medline].
Putzu A, Boscolo Berto M, Belletti A, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017 Feb 27. 10(4):355-63. [Medline].
Friedewald VE, Goldfarb S, Laskey WK, et al. The editor’s roundtable: contrast-induced nephropathy. Am J Cardiol. 2007 Aug 1. 100(3):544-51. [Medline].
Qian G, Liu CF, Guo J, Dong W, Wang J, Chen YD. Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and Congestive Heart Failure. Clin Cardiol. 2018 Jul 27. [Medline]. [Full Text].
Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011 Sep 15. 151(3):348-53. [Medline].
Briasoulis A, Mallikethi-Reddy S, Sharma S, Briasouli AA, Afonso L. 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies. Am J Ther. 2015 Nov-Dec. 22(6):e158-66. [Medline].
Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. J Thromb Thrombolysis. 2014 Nov. 38(4):493-502. [Medline].
Yang Y, Wu YX, Hu YZ. Rosuvastatin treatment for preventing contrast-induced acute kidney injury after cardiac catheterization: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015 Jul. 94(30):e1226. [Medline].
From AM, Bartholmai BJ, Williams AW, et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008 Jan. 3(1):10-8. [Medline].
Solomon R, Gordon P, Manoukian SV, et al for the BOSS Trial Investigators. Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol. 2015 Sep 4. 10(9):1519-24. [Medline].
Ali-Hassan-Sayegh S, Mirhosseini SJ, Rahimizadeh E, et al. Current status of sodium bicarbonate in coronary angiography: an updated comprehensive meta-analysis and systematic review. Cardiol Res Pract. 2015. 2015:690308. [Medline]. [Full Text].
Xu R, Tao A, Bai Y, Deng Y, Chen G. Effectiveness of N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016 Sep 23. 5(9):[Medline]. [Full Text].
Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens. 2007 Jul. 16(4):336-47. [Medline].
Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004 Feb. 15(2):407-10. [Medline].
Haase M, Haase-Fielitz A, Ratnaike S, et al. N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant. 2008 May. 23(5):1581-7. [Medline].
Rodby RA. Preventing complications of radiographic contrast media: is there a role for dialysis?. Semin Dial. 2007 Jan-Feb. 20(1):19-23. [Medline].
Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis. 2006 Sep. 48(3):361-71. [Medline].
Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007 Sep 11. 50(11):1015-20. [Medline].
Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006 Feb. 119(2):155-62. [Medline].
Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003 Sep. 60(3):176-82. [Medline].
Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004 Nov 2. 110(18):2837-42. [Medline].
Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. BMJ. 2015 Aug 27. 351:h4395. [Medline]. [Full Text].
Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol. 2015 Sep. 205(3):469-78. [Medline].
Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989 Jun. 86(6 Pt 1):649-52. [Medline].
Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999. 9(8):1602-13. [Medline].
Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM. 2008 Jul. 101(7):519-27. [Medline].
Kaplan AA, Kohn OF. Fractional excretion of urea as a guide to renal dysfunction. Am J Nephrol. 1992. 12(1-2):49-54. [Medline].
Bainey KR, Rahim S, Etherington K, et al, for the CAPTAIN Investigators. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015 Jul. 170(1):110-6. [Medline].
Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006 Jun. 21(6):i2-10. [Medline].
[Guideline] Stacul F, van der Molen AJ, Reimer P, et al, for the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011 Dec. 21(12):2527-41. [Medline]. [Full Text].
Wacker-Gussmann A, Buhren K, Schultheiss C, et al. Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients. AJR Am J Roentgenol. 2014 Feb. 202(2):452-8. [Medline].
Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003 Sep. 60(3):176-82. [Medline].
McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013 Apr. 267(1):119-28. [Medline].
Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002 Feb 11. 162(3):329-36. [Medline].
Klima T, Christ A, Marana I, te al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J. 2012 Aug. 33(16):2071-9. [Medline].
Class of Contrast Agent
Type of Contrast Agent
Iodine Dose
(mg/mL)
Iodine/Particle Ratio
Viscosity
(cPs at 37°C)
Osmolality
(mOsm/kg H2 O)
Molecular Weight (Da)
High-osmolar monomers
(ionic)
Diatrizoate (Renografin)
Ioxithalamate (Telebrix)
370
350
1.5
1.5
2.3
2.5
1870
2130
636
643
Low-osmolar dimers
(ionic)
Ioxaglate (Hexabrix)
320
3
7.5
600
1270
Low-osmolar monomers
(nonionic)
Iohexol (Omnipaque)
Iopamidol (Isovue)
Iomeprol (Iomeron)
Ioversol (Optiray)
Iopromide (Ultravist)
Iopentol (Imagopaque)
350
370
400
350
370
350
3
3
3
3
3
3
10.4
9.4
12.6
9
10
12
780
790
620
790
770
810
821
777
778
807
791
835
Iso-osmolar dimers
(nonionic)
Iodixanol (Visipaque)
Iotrolan (Isovist)
320
320
6
6
11.8
8.5
290
290
1550
1620
Anita Basu, MD, FACP Assistant Professor of Medicine, University of Mississippi School of Medicine; Staff Nephrologist, GV (Sonny) Montgomery Veterans Affairs Medical Center
Anita Basu, MD, FACP is a member of the following medical societies: American College of Physicians, National Kidney Foundation
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Eleanor Lederer, MD, FASN Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital
Eleanor Lederer, MD, FASN is a member of the following medical societies: American Association for the Advancement of Science, American Federation for Medical Research, American Society for Biochemistry and Molecular Biology, American Society for Bone and Mineral Research, American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, Kentucky Medical Association, National Kidney Foundation, Phi Beta Kappa
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Society of Nephrology<br/>Received income in an amount equal to or greater than $250 from: Healthcare Quality Strategies, Inc<br/>Received grant/research funds from Dept of Veterans Affairs for research; Received salary from American Society of Nephrology for asn council position; Received salary from University of Louisville for employment; Received salary from University of Louisville Physicians for employment; Received contract payment from American Physician Institute for Advanced Professional Studies, LLC for independent contractor; Received contract payment from Healthcare Quality Strategies, Inc for independent cont.
Vecihi Batuman, MD, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology, Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.
Renu Bansal, MD Resident Physician, Department of Internal Medicine, University of Connecticut School of Medicine
Disclosure: Nothing to disclose.
Andre A Kaplan, MD, FACP, FASN Professor of Medicine, University of Connecticut School of Medicine; Director of Dialysis Program, Chief of Blood Purification, John Dempsey Hospital; Medical Director, UConn Dialysis Center; Medical Director, McDougal Correctional Institution Dialysis Unit
Andre A Kaplan, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society for Artificial Internal Organs, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, New York Academy of Medicine, American Society for Apheresis, Renal Physicians Association
Disclosure: Nothing to disclose.
Fabio Aglieco, DO Nephrologist and Internal Medicine Primary Care Provider, Nephrology Leaders and Associates; Medical Director, Brazoria County Dialysis Center
Fabio Aglieco, DO is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.
Contrast-Induced Nephropathy
Research & References of Contrast-Induced Nephropathy|A&C Accounting And Tax Services
Source